Your browser doesn't support javascript.
loading
Multidimensional analyses reveal modulation of adaptive and innate immune subsets by tuberculosis vaccines.
Rozot, Virginie; Nemes, Elisa; Geldenhuys, Hennie; Musvosvi, Munyaradzi; Toefy, Asma; Rantangee, Frances; Makhethe, Lebohang; Erasmus, Mzwandile; Bilek, Nicole; Mabwe, Simbarashe; Finak, Greg; Fulp, William; Ginsberg, Ann M; Hokey, David A; Shey, Muki; Gurunathan, Sanjay; DiazGranados, Carlos; Bekker, Linda-Gail; Hatherill, Mark; Scriba, Thomas J.
Afiliación
  • Rozot V; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa. virginie.rozot@uct.ac.za.
  • Nemes E; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Geldenhuys H; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Musvosvi M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Toefy A; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Rantangee F; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Makhethe L; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Erasmus M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Bilek N; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Mabwe S; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Finak G; Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA.
  • Fulp W; Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA.
  • Ginsberg AM; AERAS, Rockville, MD, USA.
  • Hokey DA; AERAS, Rockville, MD, USA.
  • Shey M; Aeras South Africa Endpoint Assay Laboratory, Cape Town, South Africa.
  • Gurunathan S; Sanofi Pasteur, Swiftwater, PA, USA.
  • DiazGranados C; Sanofi Pasteur, Swiftwater, PA, USA.
  • Bekker LG; The Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.
  • Hatherill M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
  • Scriba TJ; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa. thomas.scriba@uct.ac.za.
Commun Biol ; 3(1): 563, 2020 10 09.
Article en En | MEDLINE | ID: mdl-33037320
ABSTRACT
We characterize the breadth, function and phenotype of innate and adaptive cellular responses in a prevention of Mycobacterium tuberculosis infection trial. Responses are measured by whole blood intracellular cytokine staining at baseline and 70 days after vaccination with H4IC31 (subunit vaccine containing Ag85B and TB10.4), Bacille Calmette-Guerin (BCG, a live attenuated vaccine) or placebo (n = ~30 per group). H4IC31 vaccination induces Ag85B and TB10.4-specific CD4 T cells, and an unexpected NKTlike subset, that expresses IFN-γ, TNF and/or IL-2. BCG revaccination increases frequencies of CD4 T cell subsets that either express Th1 cytokines or IL-22, and modestly increases IFNγ-producing NK cells. In vitro BCG re-stimulation also triggers responses by donor-unrestricted T cells, which may contribute to host responses against mycobacteria. BCG, which demonstrated efficacy against sustained Mycobacterium tuberculosis infection, modulates multiple immune cell subsets, in particular conventional Th1 and Th22 cells, which should be investigated in discovery studies of correlates of protection.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Tuberculosis Pulmonar / Vacunas contra la Tuberculosis / Inmunidad Adaptativa / Inmunidad Innata Tipo de estudio: Clinical_trials Límite: Adolescent / Child / Humans Idioma: En Revista: Commun Biol Año: 2020 Tipo del documento: Article País de afiliación: Sudáfrica

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Tuberculosis Pulmonar / Vacunas contra la Tuberculosis / Inmunidad Adaptativa / Inmunidad Innata Tipo de estudio: Clinical_trials Límite: Adolescent / Child / Humans Idioma: En Revista: Commun Biol Año: 2020 Tipo del documento: Article País de afiliación: Sudáfrica